恆達科技控股(01725.HK)斥逾百萬購兩衛星業務
恆達科技控股(01725.HK)公佈,持有公司70.95%股權的控股股東香港航天科技集團,分別與公司間接全資附屬香港航天發展及直接全資附屬Supreme Class International Limited訂立協議,香港航天科技集團將分別向兩間公司出售深圳港航科銷售權益及香港衛星銷售股份,代價分別爲100萬元人民幣及2萬元。
完成後,深圳港航科及香港衛星將成爲公司之間接全資附屬公司,公司將透過收購事項收購「金紫荊星座」項目項下最初發射的兩顆衛星,並將參與「金紫荊星座」,包括衛星發射及衛星數據接收及應用服務,從事航天業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.